TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Investor Presentation

#1 Producer of natural gas in the United States(4) 1. Source: Platts Analytics 2. On a scope 1 and 2 basis for the Production segment operations of EQT’s assets as of June 30, 2021. 3. Source: IHS Markit 4. Source: EIA SCALE If EQT were a country, it would be the 12th largest producer in the world(3) EQT has more production than these countries

T-MOBILE US, INC.

Condensed Consolidated Statement of Stockholders’ Equity 6 Notes to the Condensed Consolidated Financial Statements 9 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3. Quantitative and Qualitative Disclosures About Market Risk 62 Item 4. Controls and Procedures 62

  Condensed, Consolidated, Condensed consolidated

CONDENSED INTERIM CONSOLIDATED FINANCIAL …

The accounting policies applied in these condensed interim consolidated financial statements are consistent with those applied in the preparation of, and disclosed in, the consolidated annual financial statements for the year ended December 31, 2020. These consolidated interim financial statements have been prepared on a going concern basis.

  Financial, Condensed, Interim, Interim financial, Interim condensed

Bill.com (NYSE: BILL) Investor Deck Nov 2021

16 Our Financial Profile 1 Total revenue for the 12 months ended September 30, 2021.. 2. For the Fiscal Quarter ended September 30, 2021. 3. Core revenue defined as revenue derived from subscriptions and transactions.

  Bill

Newmont Sustainability-Linked Bond Framework

unless expressly set forth in the indenture and the notes governing such bonds, it will not be an event of default or breach of contractual obligations under the terms and conditions of any such bonds if Newmont fails to adhere to this Framework.

  Indenture

2020 ANNUAL REPORT

pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to ... •the risk that the failure to manage key executive succession and retention and to continue to attract qualified ... law, significant legal and financial exposure, and a loss of confidence in our security ...

  Regulations, Succession

Battery Basics, Cell Chemistry, and Cell Design

Cell Design Confidential & Proprietary Moderate rate cells have an electrode surface area roughly twice that of a bobbin cell, and are capable of delivering moderate continuous current, typically in the milliamp range, but as high as 1 amp for larger cells. Moderate rate cells are used in a wide array of applications, but are most prevalent in the

  Basics, Design, Chemistry, Battery, Cells, Battery basics, Cell chemistry, And cell design

Delivering today, building for a stronger tomorrow

allow them to take care of themselves and their families. At the same time, we worked to protect the public, including and especially the nurses, doctors and first responders on the front lines. 3M is a longtime leader in personal safety, with a range of science-based solutions for respiratory, face, hearing and fall protection. These

  Care, Respiratory

2021 Proxy Statement

Items 4A-4C Approval of Amendments to Our Amended and Restated Certificate of Incorporation (the “Charter”) to (i) provide shareholders with the right to call a special meeting, (ii) eliminate certain supermajority vote requirements and (iii) eliminate certain provisions that are no longer applicable and make certain other technical revisions

  Testament, Amendment, Proxy, Proxy statement

Agilent Technologies, Inc.

Oct 31, 2020 · Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth ...

Value-based pricing in pharmaceuticals

pricing structures and restrictive legislation: Existing pricing structure To achieve greater buying power, many countries set drug prices centrally. For example, in the UK the NHS caps spending growth on drugs via the Pharmaceutical Price Regulation …

  Based, Pharmaceutical, Value, Pricing, Value based pricing

Update of Drug Pricing System in Japan - Pmda

Pricing Rule for New Pharmaceuticals SAKIGAKE Designation System: promoting R&D in Japan aiming at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines. –“SAKIGAKE” means “taking the lead [initiative],” 13

  Pharmaceutical, Pricing

The next phase: Opportunities in China's pharmaceuticals ...

22 3.4 Pricing 22 3.5 Reimbursement 23 4. Summary 25 M&A highlights 28 1. Domestic M&A surges as pharmaceutical players lead a new wave of consolidation 31 2. Inbound M&A activity making a gradual recovery 34 2.1 Inbound acquisitions

  Pharmaceutical, Pricing

ASEAN Pharma Report: Opportunities & Threats 2020 and …

Pharmaceutical Association of Malaysia (Phama) has many concerns with the drug pricing strategy, notably that patient access to the newest medicines may be put at risk as international manufacturers may possibly withdraw their products from the market due to unfavourable business conditionsix. Both foreign and domestic pharmaceutical

  Pharmaceutical, Pricing

Operational principles for good pharmaceutical procurement

Pharmaceutical procurement is a complex process which involves many steps, agencies, ministries and manufacturers. Existing government policies, rules and regulations for procurement as well as institutional structures are frequently ... Unbiased market information onproduct availability, comparative pricing,

  Pharmaceutical, Pricing

Pharmaceutical pricing and reimbursement policies in ...

Pharmaceuticals pricing and reimbursement policies in Europe WHO TBS – October 2016 Direct price control • Example 1: External Reference Pricing • The practice of using the price(s) of a pharmaceutical product in one or several countries in order to derive a benchmark (or reference price) for the purposes of setting

  Pharmaceutical, Policies, Reimbursement, Europe, Pricing, Pricing and reimbursement policies in europe, Pharmaceutical pricing and reimbursement policies in

PHARMACEUTICAL REIMBURSEMENT AND PRICING IN …

6 │ PHARMACEUTICAL REIMBURSEMENT AND PRICING IN GERMANY © OECD 2018 “added therapeutic benefit” of new medicines in order to negotiate the price according to

  Code, Pharmaceutical, Reimbursement, Pricing, Pharmaceutical reimbursement and pricing in

THE PANDEMIC AND THE SUPPLY CHAIN Addressing Gaps in ...

pharmaceutical ingredients6 and finished pharmaceutical products. China is a major source of active pharmaceutical ingredients7 for antibiotics, antihypertensives and antivirals. Due to the pandemic8, many factories in China had to close temporarily8, leading to a halt in production5 of active pharmaceutical ingredientsand finished products.

  Pharmaceutical

Pharmaceutical regulation in 15 European countries

Pharmaceutical regulation in 15 European countries Review Vol. 18 No. 5 2016 Health Systems in Transition Dimitra Panteli • Francis Arickx • Irina Cleemput Guillaume Dedet • Helene Eckhardt • Emer Fogarty Sophie Gerkens • Cornelia Henschke • Jennifer Hislop Claudio Jommi • Daphne Kaitelidou • Pawel Kawalec Ilmo Keskimäki • Madelon Kroneman • Julio Lopez Bastida

  Pharmaceutical, European, Regulations, Countries, Pharmaceutical regulation in 15 european countries